Greetings
In order to overcome illness, there are three important conditions.
・The most important thing is for the patient to strongly desire to get well.
・Secondly, that there is the warm support of the family.
・Finally, there needs to be adequate support from medical practitioners.
My own mentor first taught me this when I became a doctor. Since that time, I have always aimed to provide care that is respectful, easy-to-understand, and supportive to the patient.
Cancer immune cell therapy is a field undergoing remarkable progress. By constantly updating our medical knowledge and providing the most appropriate treatments, I am committed to supporting both patients and their families through ongoing daily efforts.
Biography
Born in Nagoya. Raised in Canada, and Fukui.
Doctor of Medicine, Certified Specialist of the Japanese Society of Hematology Society, Certified General Internal Medicine Specialist of the Japanese Society of Internal Medicine, Certified Internist of the Japanese Society of Internal Medicine, Certified Industrial Physician of the Japan Medical Association.
Education
| 1998 | Graduated from Fukui University School of Medicine |
|---|---|
| 2006 | Graduated from Kyoto University Graduate School of Medicine |
Experience
| 1998 | Department of Internal Medicine, Kyoto University Hospital |
|---|---|
| 1999 | Department of Internal Medicine, Kishiwada City Hospital, Osaka |
| 2001 | Graduate School of Medicine, Kyoto University, Department of Hematology and Oncology. Involved in research on Human T-lymphotropic virus (HTLV-1). Obtained Doctorate in Medicine in 2006. |
| 2006 | Sugita Genpaku Memorial Obama Municipal Hospital, Fukui, Department of Internal Medicine |
| 2007 | University of Alabama at Birmingham, USA, Pathology Department, Postdoctoral Fellow |
| 2008 | National Institutes of Health (NIH), National Cancer Institute (NCI), USA, Postdoctoral Fellow. Involved in research on leukemia and solid cancer oncogenes and signal transduction. |
| 2010 | Tokyo Medical and Dental University, Department of Immunotherapeutics, Assistant Professor. Involved in basic research and clinical research on dendritic cell immunotherapy for adult T cell leukemia (ATL). |
| 2013 | Tokyo Cancer Clinic |
| 2014 | Director, Tokyo Cancer Clinic |
- Academic society affiliations
- Japanese Society of Hematology, Japanese Society of Medical Oncology, Japanese Cancer Association, the Japanese Society of Internal Medicine, International Society of Personalized Medicine, Japanese Society of Immunotherapy for Hematological Disorders.
Conference Presentations (Since 2021)
- Personalized Medicine in Cancer Treatment and Chronic Pain Management: Our Clinic’s Approach to Regenerative Medicine.
Sasada A, 26th International Society of Personalized Medicine, November 2021, Practical Session - Report on Adverse Effects and Neutralizing Antibody Levels following COVID-19 Vaccination at Our Clinic.
Sasada A, Abe M, Abe H, 26th International Society of Personalized Medicine, November 2021 - Efficacy of Combined Immunotherapy for Invasive Ductal Carcinoma (IDC) with Tumor Fever.
Sasada A, Abe M, Abe H, Azuma T, 27th International Society of Personalized Medicine, November 2022 - Evaluation of Treatment Response Assessment Tests in Cancer Immune Cell Therapy.
Sasada A, Saeki Y, Abe M, Abe H, 29th International Society of Personalized Medicine, November 2024
Publications
(List of authored publications related to cancer, immunology, and cancer immune cell therapy.)
- A study on T-cell dysfunction in carriers of Human T-cell Leukemia Virus (HTLV-1)
Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers.
Takamori A, Hasegawa A, Utsunomiya A, Maeda Y, Yamano Y, Masuda M, Shimizu Y, Tamai Y, Sasada A, Zeng N, Choi I, Uike N, Okamura J, Watanabe T, Masuda T, Kannagi M.
Retrovirology. 2011 Dec 7;8:100. doi: 10.1186/1742-4690-8-100. - A study on functional analysis of T cells in leukemia patients following bone marrow transplantation
Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation.
Tamai Y, Hasegawa A, Takamori A, Sasada A, Tanosaki R, Choi I, Utsunomiya A, Maeda Y, Yamano Y, Eto T, Koh KR, Nakamae H, Suehiro Y, Kato K, Takemoto S, Okamura J, Uike N, Kannagi M.
J Immunol. 2013 Apr 15;190(8):4382-92. doi: 10.4049/jimmunol.1202971. Epub 2013 Mar 8. - A clinical trial of dendritic cell vaccine therapy in patients with leukemia
Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study.
Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, Takamori A, Tanosaki R, Utsunomiya A, Choi I, Fukuda T, Miura O, Takaishi S, Teshima T, Akashi K, Kannagi M, Uike N, Okamura J.
Br J Haematol. 2015 May;169(3):356-67. doi: 10.1111/bjh.13302. Epub 2015 Jan 22. - A case report from our clinic describing remission achieved through combination therapy with standard treatment and dendritic cell vaccine therapy in a patient with advanced gastric cancer
A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies.
Sasada A, Takagi M, Tabata S, Abe M, Abe H.
Personalized Medicine Universe, Volume 4, July 2015, Pages 70-72 - A case report from our clinic demonstrating the effectiveness of combination therapy with standard treatment and dendritic cell vaccine therapy in a patient with advanced ovarian cancer
A case of advanced ovarian cancer effectively treated with a combination of multi-peptide dendritic cell immunotherapy, surgery, and chemotherapy.
Sasada A, Abe M, Abe H.
Personalized Medicine Universe, Volume 6, July 2017, Pages 28-30